Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Malignant Melanoma

Free Subscription Articles published in Nat Med Retrieve available abstracts of 26 articles: HTML format Text format

Single Articles

July 2019
1. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
   Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
   Nat Med. 2019 Jul 2. pii: 10.1038/s41591-019-0535.
   PubMed     Text format     Abstract available
   
   
   June 2019
2. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
   Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
   Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0476.
   PubMed     Text format     Abstract available
   
   
   
3. ASCIERTO PA, Ferrucci PF, Fisher R, Del Vecchio M, et al
   Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
   Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0448.
   PubMed     Text format     Abstract available
   
   
   
4. ROZEMAN EA, Blank CU
   Combining checkpoint inhibition and targeted therapy in melanoma.
   Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0482.
   PubMed     Text format    
   
   
   
5. SULLIVAN RJ, Hamid O, Gonzalez R, Infante JR, et al
   Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
   Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0474.
   PubMed     Text format     Abstract available
   
   
   May 2019
6. ZAPPASODI R, Sirard C, Li Y, Budhu S, et al
   Rational design of anti-GITR-based combination immunotherapy.
   Nat Med. 2019;25:759-766.
   PubMed     Text format     Abstract available
   
   
   March 2019
7. NEWMAN S, Fan L, Pribnow A, Silkov A, et al
   Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.
   Nat Med. 2019 Mar 4. pii: 10.1038/s41591-019-0373.
   PubMed     Text format     Abstract available
   
   
   
8. LONG GV
   Making a difference to many.
   Nat Med. 2019;25:356.
   PubMed     Text format    
   
   
   
9. TURAJLIC S
   Standing on the shoulders of giants.
   Nat Med. 2019;25:357.
   PubMed     Text format    
   
   
   February 2019
10. HUANG AC, Orlowski RJ, Xu X, Mick R, et al
    A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
    Nat Med. 2019 Feb 25. pii: 10.1038/s41591-019-0357.
    PubMed     Text format     Abstract available
    
    
    December 2018
11. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 18. pii: 10.1038/s41591-018-0325.
    PubMed     Text format     Abstract available
    
    
    
12. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
    Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
    Nat Med. 2018 Dec 3. pii: 10.1038/s41591-018-0265.
    PubMed     Text format     Abstract available
    
    
    November 2018
13. ROBERT C
    Is earlier better for melanoma checkpoint blockade?
    Nat Med. 2018;24:1645-1648.
    PubMed     Text format     Abstract available
    
    
    October 2018
14. CEREZO M, Guemiri R, Druillennec S, Girault I, et al
    Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Nat Med. 2018 Oct 29. pii: 10.1038/s41591-018-0217.
    PubMed     Text format     Abstract available
    
    
    
15. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0252.
    PubMed     Text format     Abstract available
    
    
    
16. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0251.
    PubMed     Text format     Abstract available
    
    
    
17. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Oct 17. pii: 10.1038/s41591-018-0247.
    PubMed     Text format     Abstract available
    
    
    
18. BLANK CU, Rozeman EA, Fanchi LF, Sikorska K, et al
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0198.
    PubMed     Text format     Abstract available
    
    
    
19. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0197.
    PubMed     Text format     Abstract available
    
    
    August 2018
20. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Aug 20. pii: 10.1038/s41591-018-0157.
    PubMed     Text format     Abstract available
    
    
    January 2018
21. BOSHUIZEN J, Koopman LA, Krijgsman O, Shahrabi A, et al
    Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
    Nat Med. 2018 Jan 15. pii: nm.4472. doi: 10.1038/nm.4472.
    PubMed     Text format     Abstract available
    
    
    October 2017
22. MURGAI M, Ju W, Eason M, Kline J, et al
    KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis.
    Nat Med. 2017;23:1176-1190.
    PubMed     Text format     Abstract available
    
    
    August 2017
23. XUE Y, Martelotto L, Baslan T, Vides A, et al
    An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Nat Med. 2017;23:929-937.
    PubMed     Text format     Abstract available
    
    
    July 2017
24. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
    ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
    Nat Med. 2017;23:890-898.
    PubMed     Text format     Abstract available
    
    
    December 2016
25. PEINADO H, Alec kovic M, Lavotshkin S, Matei I, et al
    Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
    Nat Med. 2016;22:1502.
    PubMed     Text format    
    
    
    October 2016
26. LINNEMANN C, van Buuren MM, Bies L, Verdegaal EM, et al
    Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
    Nat Med. 2016;22:1192.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: